NEWSROOM

Healthcare

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

Jan 13, 2026

Anticipated strong revenue growth driven by higher unit sales of SSi Mantra surgical robotic system Fort Lauderdale, FL, January 13, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced preliminary unaudited revenue and other...

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Jan 13, 2026

Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million...

SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer

SS Innovations Appoints Milan Rao as Global Chief Operating Officer and Chief Financial Officer

Jan 8, 2026

SS Innovations International, Inc. appoints seasoned executive Milan Rao to drive global growth, operational scale, and expanded access to affordable robotic surgery. Fort Lauderdale, FL, January 8, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global...

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Aclarion Provides 2025 Update and 2026 Corporate Outlook

Jan 8, 2026

Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025 Annual Nociscan scan volumes increased 69% year-over-year in 2025 Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth Company aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo.,...

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Jan 7, 2026

Decision ensures continued patient access to VENDAJE® and VENDAJE AC® POMPANO BEACH, Fla., Jan. 07, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today commented on the withdrawal of all seven of the Centers for Medicare & Medicaid Services’ (“CMS”) Local Coverage...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Develops New Instruments to Advance Robotic Surgery in Large, Underserved Patient Segments, including Pediatric and Cardiac Markets

Jan 6, 2026

Smaller 5-millimeter instruments to be incorporated into the SSi Mantra surgical robotic system Takeways: SS Innovations International enhances the SSi Mantra platform with new 5mm robotic instruments for high-precision, small-anatomy surgeries SS Innovations International leverages SSi Mantra to expand access to pediatric and cardiac robotic surgery in underserved global markets Ongoing innovation by SS Innovations International positions SSi Mantra as a cost-effective, scalable solution for...

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Jan 6, 2026

Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion,...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

Dec 18, 2025

Status Quo designation preserves DFU/VLU reimbursement eligibility for 2026, ensuring continued patient access to BioStem technology Coverage for the majority of BioStem’s non-acute revenue, treatment for pressure ulcers, also remains unaffected by CMS LCD updates POMPANO BEACH, FL, December 18, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

Dec 10, 2025

Expanding its Portfolio with American Amnionto Serve the Wound Care Needs of Our Veterans BioStem Technologies launched two new placental-derived allografts—American Amnion and American Amnion AC—featuring its BioRetain processing technology. The products aim to enhance chronic wound healing with improved structural integrity and cell preservation, offering clinicians more consistent outcomes. The launch was showcased at the 2025 Desert Foot Conference, emphasizing support for veteran care...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Submits 510(k) Premarket Notification to the FDA for the Company’s SSi Mantra Surgical Robotic System

Dec 8, 2025

-- Submission covers multiple indications including general, urological, colorectal, gynecological and cardiac surgeries -- SS Innovations has officially submitted a 510(k) application to the U.S. FDA for its SSi Mantra surgical robotic system, aiming for clearance to enter the U.S. market. The SSi Mantra system supports multiple surgical specialties, including general, urological, colorectal, gynecological, and cardiac procedures. The company is simultaneously pursuing EU CE Mark approval to...

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Dec 4, 2025

Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine care IJSS publishes over 150 articles annually representing 40+ nations BROOMFIELD, Colo., December 4, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Dec 2, 2025

Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough technologies across spine, neurosurgery and pain management Strengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S BROOMFIELD, Colo., December 2, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc.,...

Junction Brain Health Opens Toledo Clinic

Junction Brain Health Opens Toledo Clinic

Dec 1, 2025

Junction Brain Health has opened a new clinic in Toledo, expanding access to advanced, non-invasive treatments for depression across Northwest Ohio and Southeast Michigan. The clinic offers FDA-approved TMS and Spravato® (esketamine) therapies for individuals with treatment-resistant depression, providing coordinated, science-driven brain health care. Staffed by experienced psychiatric providers and TMS technicians, the center delivers individualized care and is now accepting both provider and...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Expands Product Access in Medicaid

Nov 25, 2025

Florida Medicaid Adds BioStem’s VENDAJEⓇ and VENDAJE ACⓇ to Covered Skin Substitutes List Key Takeaways Major reimbursement milestone — Florida Medicaid now covers VENDAJE® and VENDAJE AC®, expanding BioStem’s reach to 13 Medicaid programs nationwide. Significant market expansion — Florida, one of the largest Medicaid states, meaningfully grows BioStem’s addressable patient population and validates its clinical and economic value. Growth catalyst for 2026 — Expanded coverage strengthens...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Reports Third Quarter 2025 Financial Results

Nov 13, 2025

Key Takeaways Consistent Profitability — Q3 2025 net revenue reached $10.5M with $0.8M net income, marking BioStem’s seventh consecutive quarter of positive adjusted EBITDA. Clinical & Regulatory Progress — Positive BioREtain® trial results published in the International Journal of Tissue Repair; FDA reinspection completed with no observations. Strategic Expansion & Partnerships — BioStem secured land for its new Boca Raton HQ, partnered with a Service-Disabled Veteran-Owned Small...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Announces Filing of Restated Financial Statements

Nov 13, 2025

Key Takeaways Restated Financials Filed — BioStem filed restated interim and annual financial statements for 2023–2025, aligning with US GAAP for revenue recognition. Revenue Classification Update — Bona fide services fees from Venture Medical are now treated as contra revenue, lowering gross sales but not impacting EBITDA or cash flow. Audit and Uplist Progress — BioStem’s KPMG-led independent audit will conclude by Q1 2026, supporting plans to uplist and strengthen investor transparency....

American Shared Hospital Services Reports Third Quarter 2025 Financial Results

American Shared Hospital Services Reports Third Quarter 2025 Financial Results

Nov 13, 2025

Third Quarter Revenue Increased 2.5% Period over Period with 42.3% EBITDA Growth Revenue for the First Nine Months Increased 5.6% Year Over Year Signs Existing Health System to 10 Year Extension and an Upgrade to their Gamma Knife System Conference Call Scheduled for 1:00 PM ET Today SAN FRANCISCO, CA, November 13, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Announces Successful Completion of First Telesurgery Performed with the Company’s SSi Mantra Tele Surgeon Console

Nov 6, 2025

Compact New Console Facilitates Performance of Telesurgeries from a Wide Range of Locations, including Physicians’ Offices Key Takeaways Historic First for Robotic TelesurgerySS Innovations (Nasdaq: SSII) successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), enabling remote operations from any connected location. Compact, Office-Ready DesignThe TSC is a self-contained, chair-based console with 3D visualization and magnetic sensor controls, allowing...

American Shared Hospital Services Reports Third Quarter 2025 Financial Results

American Shared Hospital Services Announces Third Quarter Financial Results Conference Call

Nov 6, 2025

Call Scheduled for November 13th at 1:00 PM ET SAN FRANCISCO, November 6, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its equipment leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its third...

BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference

BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes

Nov 5, 2025

Key Takeaways CMS’s final rule praised for transparency — BioStem welcomed the 2026 Medicare reimbursement reform for skin substitutes as a move toward a fair, predictable system rewarding proven outcomes. BioREtain® supports evidence-based care — The company’s BioREtain® allografts, validated in a Level 1 randomized trial showing superior outcomes, align with CMS’s push for clinically proven, cost-efficient products. Strong economics under new model — Vertically integrated GMP manufacturing...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters

Nov 5, 2025

Future Relocation and Expansion to Create Up to 100 New Jobs Over 5 Years City Approves Up to $300,000 in Economic Incentives to Rapidly Growing MedTech Business POMPANO BEACH, Fla., Nov. 5, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the purchase of land for...

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Nov 5, 2025

Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan Nociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives Broomfield, CO, November 5, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) -...

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University

Nov 3, 2025

Key Takeaways Q4 government submission in progress — Halberd Corporation, with Mississippi State University, is preparing a U.S. government funding submission to advance post-head-trauma TBI treatment. Phase-2 animal research focus — The sought contract would finance studies measuring biochemical and behavioral efficacy of a multi-part nasal spray across blast and impact TBI models. AI-enhanced assessment & military use case — NeuroSense AI will support multi-modal behavioral analysis;...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers

Oct 31, 2025

Key Takeaways Superior healing with BioRetain® (BR-AC) — In the randomized trial, the probability of complete, lasting closure was 53% with BR-AC vs 31% with standard care, demonstrating a clear clinical benefit. Rigorous design focused on hard-to-heal DFUs — Multicenter RCT (11 U.S. sites) used a 2-week run-in; patients improving >30% on standard care were excluded. Closure had to remain sealed for 4 weeks to count as “lasting.” Clinical momentum and market need — BioStem is also enrolling...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025

Oct 30, 2025

Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., October 30, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announces it will release its third quarter 2025 financial results on Thursday, November 13, 2025, and will host a conference call and webcast...

SS Innovations Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2025

SS Innovations Reports Third Quarter 2025 Financial Results

Oct 28, 2025

Quarterly Revenue Increased 192.5% Year over Year to $12.8 Million Driven by Higher SSi Mantra 3 Unit Sales Fort Lauderdale, FL, October 28, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for...

BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant

Oct 27, 2025

POMPANO BEACH, FL, October 27, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - BioStem Technologies, Inc. (OTC: BSEM) (the “Company”), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the Audit Committee of its Board of Directors has approved the appointment of KPMG LLP (“KPMG”) as the Company's independent registered public accounting firm, and it...

Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University

Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Oct 27, 2025

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies Halberd Demonstrates NeuroSense AI FeasibilityHalberd Corporation successfully validated its NeuroSense AI system in a live demonstration, showcasing advanced multi-modal behavioral analysis technology designed to revolutionize traumatic brain injury (TBI) research and neurological diagnostics. AI-Powered Insights into Brain and Behavioral FunctionThe NeuroSense AI...

Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

Synbio International Inc. Expands its Board of Directors and Strengthens its Clinical Leadership with the Appointment of Dr. Nick Vatakis

Oct 22, 2025

Dr. Vatakis, appointed as Medical Director, brings decades of clinical trial leadership, advancing Synbio’s credibility and the integrity of its upcoming feasibility trial New York City, October 22, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Synbio International Inc. (OTC: SYIN) (“Synbio” or the “Company”) is proud to announce the appointment of Dr. Nick Vatakis, MD as Medical Director. This appointment represents a major milestone in Synbio’s commitment to...

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 22, 2025

Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., October 22, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to...